Somalogic Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.12
- Today's High:
- $2.255
- Open Price:
- $2.15
- 52W Low:
- $1.925
- 52W High:
- $3.869
- Prev. Close:
- $2.19
- Volume:
- 877455
Company Statistics
- Market Cap.:
- $425.04 million
- Book Value:
- 2.739
- Revenue TTM:
- $101.39 million
- Operating Margin TTM:
- -153.8%
- Gross Profit TTM:
- $-11271000
- Profit Margin:
- -139.23%
- Return on Assets TTM:
- -15.33%
- Return on Equity TTM:
- -25.16%
Company Profile
Somalogic Inc had its IPO on 2021-04-23 under the ticker symbol SLGC.
The company operates in the Healthcare sector and Health Information Services industry. Somalogic Inc has a staff strength of 451 employees.
Stock update
Shares of Somalogic Inc opened at $2.15 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.12 - $2.26, and closed at $2.24.
This is a +2.28% increase from the previous day's closing price.
A total volume of 877,455 shares were traded at the close of the day’s session.
In the last one week, shares of Somalogic Inc have slipped by -0.89%.
Somalogic Inc's Key Ratios
Somalogic Inc has a market cap of $425.04 million, indicating a price to book ratio of 0.753 and a price to sales ratio of 4.4197.
In the last 12-months Somalogic Inc’s revenue was $101.39 million with a gross profit of $-11271000 and an EBITDA of $-149435008. The EBITDA ratio measures Somalogic Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Somalogic Inc’s operating margin was -153.8% while its return on assets stood at -15.33% with a return of equity of -25.16%.
In Q2, Somalogic Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 44.7%.
Somalogic Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.78 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Somalogic Inc’s profitability.
Somalogic Inc stock is trading at a EV to sales ratio of 2.8045 and a EV to EBITDA ratio of -3.5572. Its price to sales ratio in the trailing 12-months stood at 4.4197.
Somalogic Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $585.75 million
- Total Liabilities
- $31.50 million
- Operating Cash Flow
- $-57972000.00
- Capital Expenditure
- $1.13 million
- Dividend Payout Ratio
- 0%
Somalogic Inc ended 2024 with $585.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $585.75 million while shareholder equity stood at $515.15 million.
Somalogic Inc ended 2024 with $0 in deferred long-term liabilities, $31.50 million in other current liabilities, 19000.00 in common stock, $-667529000.00 in retained earnings and $10.40 million in goodwill. Its cash balance stood at $354.54 million and cash and short-term investments were $474.19 million. The company’s total short-term debt was $10,926,000 while long-term debt stood at $0.
Somalogic Inc’s total current assets stands at $516.26 million while long-term investments were $9.04 million and short-term investments were $119.65 million. Its net receivables were $21.75 million compared to accounts payable of $13.08 million and inventory worth $15.12 million.
In 2024, Somalogic Inc's operating cash flow was $-57972000.00 while its capital expenditure stood at $1.13 million.
Comparatively, Somalogic Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.24
- 52-Week High
- $3.869
- 52-Week Low
- $1.925
- Analyst Target Price
- $5.63
Somalogic Inc stock is currently trading at $2.24 per share. It touched a 52-week high of $3.869 and a 52-week low of $3.869. Analysts tracking the stock have a 12-month average target price of $5.63.
Its 50-day moving average was $2.19 and 200-day moving average was $2.64 The short ratio stood at 10.82 indicating a short percent outstanding of 0%.
Around 895.9% of the company’s stock are held by insiders while 6917.6% are held by institutions.
Frequently Asked Questions About Somalogic Inc
Similar Industry Stocks (Health Information Services)
Most Active
Top Gainers
Top Losers
About
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company’s SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan’s biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.